Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03406156 · ClinicalTrials.gov registry record · Phase 3
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT03406156 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 120 participants.
The verdict
NCT03406156, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
This is a multi-cohort, open-label study in previously untreated participants with chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), excluding those with the 17p deletion, to evaluate a debulking strategy that would enable all participants to receive subsequent venetoclax as outpatients, with lower risk of tumor lysis syndrome.
Interventions
- DRUG Obinutuzumab
- DRUG Venetoclax
- DRUG Bendamustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2018-08-10 |
| Est. Completion | 2023-07-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03406156
The ClinicalTrials.gov registry entry for NCT03406156 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Obinutuzumab is the first listed.
NCT03406156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03406156 about?
NCT03406156 is a clinical study titled "A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy". This is a multi-cohort, open-label study in previously untreated participants with chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), excluding those with the 17p deletion, to evaluate a debulking strategy that would enable all participants to receive subsequent venetoclax as outp...
What is the current status of trial NCT03406156?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2018-08-10. Estimated completion is 2023-07-12.
What interventions are being tested in trial NCT03406156?
The interventions under investigation include: Obinutuzumab (DRUG), Venetoclax (DRUG), Bendamustine (DRUG).
Who is sponsoring clinical trial NCT03406156?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.